(VIANEWS) – Progyny (PGNY), Novo Nordisk A/S (NVO), Itron (ITRI) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Progyny (PGNY)
28.2% sales growth and 12.63% return on equity
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Progyny has a trailing twelve months EPS of $0.48.
PE Ratio
Progyny has a trailing twelve months price to earnings ratio of 72.25. Meaning, the purchaser of the share is investing $72.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.63%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Progyny’s EBITDA is 3.13.
2. Novo Nordisk A/S (NVO)
18.2% sales growth and 81.54% return on equity
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $2.11.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 42.43. Meaning, the purchaser of the share is investing $42.43 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 81.54%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Novo Nordisk A/S’s EBITDA is 13.45.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 47.3% and a negative 50%, respectively.
Volume
Today’s last reported volume for Novo Nordisk A/S is 3368880 which is 11.24% below its average volume of 3795920.
Yearly Top and Bottom Value
Novo Nordisk A/S’s stock is valued at $89.52 at 16:22 EST, way below its 52-week high of $100.88 and way higher than its 52-week low of $50.44.
Previous days news about Novo Nordisk A/S(NVO)
- According to Zacks on Wednesday, 4 October, "Investors in Novo Nordisk A/S (NVO Quick QuoteNVO – Free Report) need to pay close attention to the stock based on moves in the options market lately. "
3. Itron (ITRI)
17.5% sales growth and 3.34% return on equity
Itron (itri) gains 15.4% ytd: will the upward trend last?Headquartered in Liberty Lake, WA, Itron is one of the leading global suppliers of a wide range of standard, advanced and smart meters, and meter communication systems.
Itron, Inc., a technology and service company, provides end-to-end solutions that help manage operations in the energy, water, and smart city space worldwide. The company operates through three segments: Device Solutions, Networked Solutions, and Outcomes. The Device Solutions segment offers hardware products that are used for measurement, control, or sensing. The Networked Solutions segment provides a combination of communicating devices, such as smart meters, modules, endpoints, and sensors; network infrastructure; and associated application software for acquiring and transporting application-specific data. The Outcomes segment offers enhanced software and services for managing, organizing, analyzing, and interpreting data to enhance decision making, maximize operational profitability, drive resource efficiency, and deliver results for consumers, utilities, and smart cities. In addition, it offers implementation, project management, installation, consulting, and post-sale maintenance support services, as well as cloud and software-as-a-service; and extended or customer-specific warranties. It offers its products and services under the Itron brand. The company markets its products directly through its sales force, as well as through indirect sales force consisting of distributors, sales representatives, partners, and meter manufacturer representatives to utilities and municipalities. Itron, Inc. was incorporated in 1977 and is headquartered in Liberty Lake, Washington.
Earnings Per Share
As for profitability, Itron has a trailing twelve months EPS of $0.85.
PE Ratio
Itron has a trailing twelve months price to earnings ratio of 70.33. Meaning, the purchaser of the share is investing $70.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.34%.
Moving Average
Itron’s worth is way under its 50-day moving average of $68.27 and under its 200-day moving average of $61.58.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 117.4% and a drop 28.2% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Itron’s EBITDA is 1.55.
Yearly Top and Bottom Value
Itron’s stock is valued at $59.78 at 16:22 EST, way below its 52-week high of $79.99 and way above its 52-week low of $39.38.
4. Ituran Location and Control Ltd. (ITRN)
14.5% sales growth and 29.44% return on equity
Ituran Location and Control Ltd., together with its subsidiaries, provides location-based services and wireless communications products. The company's Location-Based Services segment provides stolen vehicle recovery and tracking services, which locate, track, and recover stolen vehicles for its subscribers; fleet management services that enable corporate and individual customers to track and manage their vehicles in real time; and personal locator services that allow customers to protect valuable merchandise and equipment. It also offers on-demand navigation guidance, information, and assistance, including the provision of traffic reports and directions, as well as information on the location of gas stations, car repair shops, post offices, hospitals, and other facilities; and Connected Car, service platform includes a back-office application, a telematics device installed in the vehicle, mobile apps for both IOS and Android users, as well as usage based insurance. This segment serves insurance companies and agents, car manufacturers, dealers and importers, cooperative sales channels, and private subscribers. Its Wireless Communications Products segment provides Base Site, a radio receiver that includes a processor and a data computation unit to collect and send data to and from transponders, and to control centers; Control Center, a center consisting of software used to collect data from various base sites, conduct location calculations, and transmit location data to various customers and law enforcement agencies; navigation and tracking devices installed in vehicles; and SMART, a portable transmitter installed in vehicles that sends a signal to the base site enabling the location of vehicles, equipment, or an individual. As of December 31, 2020, it served approximately 17,680,000 end-users in Israel, Brazil, Argentina, Mexico, Ecuador, Colombia, and the United States. The company was incorporated in 1994 and is headquartered in Azor, Israel.
Earnings Per Share
As for profitability, Ituran Location and Control Ltd. has a trailing twelve months EPS of $2.14.
PE Ratio
Ituran Location and Control Ltd. has a trailing twelve months price to earnings ratio of 13.95. Meaning, the purchaser of the share is investing $13.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.44%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 18.4% and 31.9%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Ituran Location and Control Ltd.’s EBITDA is 1.86.
5. Edwards Lifesciences (EW)
13.9% sales growth and 22.4% return on equity
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Earnings Per Share
As for profitability, Edwards Lifesciences has a trailing twelve months EPS of $2.33.
PE Ratio
Edwards Lifesciences has a trailing twelve months price to earnings ratio of 30.69. Meaning, the purchaser of the share is investing $30.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.4%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Edwards Lifesciences’s EBITDA is 7.4.
Moving Average
Edwards Lifesciences’s value is way below its 50-day moving average of $80.07 and way below its 200-day moving average of $81.56.
6. Build (BBW)
9.2% sales growth and 50.47% return on equity
Build-A-Bear Workshop, Inc. operates as a multi-channel retailer of plush animals and related products. The company operates through three segments: Direct-to-Consumer, International Franchising, and Commercial. Its merchandise comprises various styles of plush products to be stuffed, pre-stuffed plush products, and sounds and scents that can be added to the stuffed animals, as well as range of clothing, shoes, accessories, and other toy and novelty items. The company operates its stores under the Build-A-Bear Workshop brand name; and sells its products through its e-commerce sites. As of January 30, 2021, it operated 354 stores, including 305 stores in the United States and Canada; and 49 stores in the United Kingdom, Ireland, and China, as well as 71 franchised stores internationally. The company was founded in 1997 and is headquartered in St. Louis, Missouri.
Earnings Per Share
As for profitability, Build has a trailing twelve months EPS of $3.42.
PE Ratio
Build has a trailing twelve months price to earnings ratio of 8.32. Meaning, the purchaser of the share is investing $8.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 50.47%.
Yearly Top and Bottom Value
Build’s stock is valued at $28.46 at 16:22 EST, below its 52-week high of $30.49 and way higher than its 52-week low of $12.61.
7. Mondelez International (MDLZ)
9.1% sales growth and 14.75% return on equity
Mondelez International, Inc., through its subsidiaries, manufactures, markets, and sells snack food and beverage products in the Latin America, North America, Asia, the Middle East, Africa, and Europe. It provides biscuits and baked snacks, including cookies, crackers, salted snacks, snack bars, and cakes and pastries; chocolates; and gums and candies, as well as various cheese and grocery, and powdered beverage products. The company's brand portfolio includes Oreo, Ritz, LU, CLIF Bar, and Tate's Bake Shop biscuits and baked snacks, as well as Cadbury Dairy Milk, Milka, and Toblerone chocolate. It serves supermarket chains, wholesalers, supercenters, club stores, mass merchandisers, distributors, convenience stores, gasoline stations, drug stores, value stores, and other retail food outlets through direct store delivery, company-owned and satellite warehouses, third party distributors, and other facilities, as well as through independent sales offices and agents. The company was formerly known as Kraft Foods Inc. and changed its name to Mondelez International, Inc. in October 2012. Mondelez International, Inc. was incorporated in 2000 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, Mondelez International has a trailing twelve months EPS of $3.01.
PE Ratio
Mondelez International has a trailing twelve months price to earnings ratio of 22.09. Meaning, the purchaser of the share is investing $22.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.75%.
